IRIS
PALUMBO, Giuseppe Alberto Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.686
AS - Asia 7.397
EU - Europa 7.365
SA - Sud America 1.204
AF - Africa 825
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 8
AN - Antartide 1
Totale 30.506
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.247
SG - Singapore 3.739
RU - Federazione Russa 2.527
CN - Cina 1.925
IT - Italia 1.799
BR - Brasile 997
IE - Irlanda 967
UA - Ucraina 578
VN - Vietnam 563
CI - Costa d'Avorio 412
FR - Francia 376
KR - Corea 328
CA - Canada 322
DE - Germania 185
BD - Bangladesh 177
IN - India 176
GB - Regno Unito 175
NG - Nigeria 167
SE - Svezia 164
FI - Finlandia 117
AR - Argentina 89
NL - Olanda 81
HK - Hong Kong 80
MX - Messico 78
SN - Senegal 77
JP - Giappone 70
PL - Polonia 68
ES - Italia 62
BE - Belgio 55
ZA - Sudafrica 49
IQ - Iraq 48
CH - Svizzera 45
TR - Turchia 37
BJ - Benin 33
CZ - Repubblica Ceca 33
PK - Pakistan 30
UZ - Uzbekistan 27
AT - Austria 26
ID - Indonesia 25
CO - Colombia 23
EC - Ecuador 23
LT - Lituania 23
MA - Marocco 21
CL - Cile 19
EG - Egitto 19
JO - Giordania 19
LB - Libano 19
VE - Venezuela 19
AU - Australia 18
GR - Grecia 18
KE - Kenya 17
AE - Emirati Arabi Uniti 15
IR - Iran 15
DZ - Algeria 13
IL - Israele 13
MY - Malesia 12
PH - Filippine 11
PY - Paraguay 11
SA - Arabia Saudita 11
OM - Oman 10
BG - Bulgaria 9
PE - Perù 9
RO - Romania 9
TT - Trinidad e Tobago 8
AZ - Azerbaigian 7
EU - Europa 7
HR - Croazia 7
AL - Albania 6
KZ - Kazakistan 6
NP - Nepal 6
PS - Palestinian Territory 6
UY - Uruguay 6
ET - Etiopia 5
HN - Honduras 5
KG - Kirghizistan 5
RS - Serbia 5
BO - Bolivia 4
CY - Cipro 4
DO - Repubblica Dominicana 4
GT - Guatemala 4
JM - Giamaica 4
NI - Nicaragua 4
SI - Slovenia 4
AM - Armenia 3
BY - Bielorussia 3
CR - Costa Rica 3
GY - Guiana 3
LV - Lettonia 3
MT - Malta 3
NO - Norvegia 3
PT - Portogallo 3
TN - Tunisia 3
AO - Angola 2
EE - Estonia 2
HU - Ungheria 2
KW - Kuwait 2
LU - Lussemburgo 2
MD - Moldavia 2
PR - Porto Rico 2
SK - Slovacchia (Repubblica Slovacca) 2
Totale 30.480
Salva come PNG Salva come JPEG
Città #
Dallas 2.309
Singapore 2.271
Santa Clara 1.515
Moscow 1.129
San Jose 1.010
Dublin 939
Chandler 924
Houston 805
Ashburn 762
Chicago 542
Jacksonville 538
Hefei 454
Abidjan 412
Boardman 386
Catania 369
Seoul 325
Los Angeles 298
Lauterbourg 288
Beijing 265
Lawrence 248
Cambridge 245
Andover 241
Nanjing 212
Ho Chi Minh City 182
Toronto 169
Council Bluffs 159
New York 141
Civitanova Marche 132
Des Moines 129
Hanoi 122
Buffalo 121
Milan 108
São Paulo 108
Wilmington 108
Rome 99
San Mateo 90
Abuja 80
Dakar 77
Lagos 76
Palermo 75
Nanchang 72
Hong Kong 68
The Dalles 63
Florence 59
Lappeenranta 59
Shenyang 58
Saint Petersburg 57
Warsaw 57
Orem 56
Tokyo 56
Montreal 55
Hebei 54
Jiaxing 52
Ottawa 52
Brussels 51
Columbus 51
Grafing 46
Amsterdam 45
Chennai 45
Munich 45
Changsha 43
Brooklyn 41
Stockholm 41
Dong Ket 40
Washington 40
Boston 39
London 38
Seattle 38
Denver 37
Helsinki 35
Tianjin 34
Cotonou 33
Atlanta 32
Paris 31
Phoenix 30
Falls Church 29
Rio de Janeiro 29
Johannesburg 28
Mexico City 28
Naples 28
Poplar 28
San Francisco 28
Messina 27
Mumbai 25
Manchester 24
Turku 23
Kochi 22
Belo Horizonte 21
Haiphong 21
Bari 19
Frankfurt am Main 19
Baghdad 18
Bronte 18
Den Haag 18
Piscataway 18
Amman 17
Curitiba 17
Querétaro 17
Redondo Beach 17
Brno 16
Totale 20.671
Salva come PNG Salva come JPEG
Nome #
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy 295
Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes 248
Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population 240
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment 217
Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells 207
IGFBP-6 Alters Mesenchymal Stromal Cell Phenotype Driving Dasatinib Resistance in Chronic Myeloid Leukemia 204
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 201
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 199
Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis 198
A cytoprotective role for the heme oxygenase-1/CO pathway during neural differentiation of human mesenchymal stem cells 187
Focus on Osteosclerotic Progression in Primary Myelofibrosis 186
ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis 181
Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells 179
A MULTICENTRIC STUDY TO EVALUATE THE EFFICACY OF EPOIETIN ZETA (BIOSIMILAR OF EPO ALPHA) IN LOW RISK MYELODISPLASTIC PATIENTS 176
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 170
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 170
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 168
Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports 167
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma 165
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 164
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 164
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 163
Hedgehog signaling pathways in multiple myeloma 163
Targeted Metabolomics Highlights Dramatic Antioxidant Depletion, Increased Oxidative/Nitrosative Stress and Altered Purine and Pyrimidine Concentrations in Serum of Primary Myelofibrosis Patients 159
A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study 159
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3 159
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling 159
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 157
A case of high-risk AML in a patient with advanced systemic mastocytosis 156
Neuroprotective Role of α-Lipoic Acid in Iron-Overload-Mediated Toxicity and Inflammation in In Vitro and In Vivo Models 155
Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia 155
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 155
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 154
A physiological role for the neuropeptide luteinizing hormone-releasing hormone (LHRH) during the maturation of thymus Gland function 151
In vitro apoptotic response of freshly isolated chronic myeloid leukemia cells to all-trans retinoic acid and cytosine arabinoside 149
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma 148
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib 147
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI) 144
Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience 143
Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas 142
BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1 AND YKL40 EXPRESSION 142
Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma 142
Correction to: Neuroprotective Role of α-Lipoic Acid in Iron-Overload-Mediated Toxicity and Inflammation in In Vitro and In Vivo Models (Antioxidants, (2022), 11, 8, (1596), 10.3390/antiox11081596) 141
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy 141
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation 139
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma 139
13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia 139
Renal extramedullary hematopoiesis as an epiphenomenon of bone marrow dysfunction in a patient with primary myelofibrosis: A rare case report 138
Bortezomib Could Reduce Cell Viability by Activation of Heme Oxygenase 1 in Multiple Myeloma Cells 138
Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib 138
Multiple Myeloma in 2023 Ways: From Trials to Real Life 136
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine 136
Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases 134
Correction: TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma (Cell Death & Disease, (2019), 10, 10, (704), 10.1038/s41419-019-1959-5) 132
Effects of micronised microencapsulated ferric pyrophosphate supplementation in patients with advanced cancer and iron deficiency: A single-centre cohort pilot study 130
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 128
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors 128
Terapia del mieloma multiplo 128
Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation 128
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint. 127
Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology 126
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions 126
Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients 125
Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field 125
Engagement of Mesenchymal Stromal Cells in the Remodeling of the Bone Marrow Microenvironment in Hematological Cancers 124
Nuclear translocation of Heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells 124
Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia 124
Low serum levels of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in IFN-treated chronic myeloid leukemia (CML) patients 123
Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting 122
Angiogenic factors (VEGF, bFGF, and HGF) in multiple myeloma: higher levels in bone marrow than in peripheral blood 122
ANTITUMOR ACTIVITY OF BORTEZOMIB ALONE AND IN COMBINATION WITH TRAIL IN HUMAN ACUTE MYELOID LEUKEMIA C.M.S 122
The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents 122
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data 121
The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma 121
Emangioma, plasmocitoma e mieloma multiplo del rachide 121
MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromes 120
Antitumor Activity of Bortezomib Alone and in Combination with TRAIL in Human Acute Myeloid Leukemia 120
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint 119
The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis 118
AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib 117
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 117
Emergencies in Hematology: Why, When and How I Treat? 116
Angiogenesis in acute myeloid leukemia 116
Pyrrolidinedithiocarbamate induces apoptosis in human acute myelogenous leukemic cells affecting NF-kappaB activity 116
Emerging Therapeutic Approaches for Anemia in Myelofibrosis 115
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 115
Evaluation of taxol cytotoxicity on B-CLL cells in vitro 114
Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality 114
5-AZACYTIDINE FOR THE TREATMENT OF INTERMEDIATE-2/HIGH IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS IN 83 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM 113
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 113
Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future 112
HIGH-RESOLUTION SNP ARRAYS AS AN ADDITIONAL TOOL TO SEARCH FOR GENETIC DEFECTS INVOLVED IN PROGRESSION FROM MYELODYSPLASTIC SINDROME TO ACUTE LEUKEMIA 112
Proteomic analysis reveals autophagy as pro-survival pathway elicited by long-term exposure with 5-azacitidine in high-risk myelodysplasia 111
Hemophagocytic Syndrome in a Patient with ALL: Morphology Still Matters 111
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 110
Endoscopic features of gastro-intestinal lymphomas: From diagnosis to follow-up 110
IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis 110
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes 110
Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview 110
Anemia and blood transfusions in myelofibrosis: economic and organizational impact on Italian patients, caregivers and hospitals 109
Totale 14.404
Salva come PNG Salva come JPEG
Categoria #
all - tutte 103.639
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 103.639
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202180 0 0 0 0 0 0 0 0 0 0 0 80
2021/20221.799 150 246 2 13 363 38 271 77 158 32 35 414
2022/20233.042 278 147 73 212 249 522 28 515 738 56 154 70
2023/20241.805 111 246 93 127 87 339 97 133 10 51 320 191
2024/20256.208 56 954 344 315 1.336 633 219 234 442 614 527 534
2025/202614.781 863 1.302 2.177 908 2.238 2.888 1.607 358 864 817 461 298
Totale 31.022